PuriBlood Medical Co.,Ltd.(TW:6847)
NT$70.40-0.70 (-0.98%)
TW:6847
PuriBlood Medical Co.,Ltd. financials statements
NT$70.40
At close:-0.70 (-0.98%)
PuriBlood Medical Co.,Ltd. (6847) Ratios
PuriBlood Medical Co.,Ltd. Ratios
TW:6847's free cash flow for Q2 2026 was NT$-16.87M. For the 2026 fiscal year, TW:6847's free cash flow was decreased by NT$-78.00K and operating cash flow was NT$-16.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.12 | 3.81 | 3.88 | 5.81 | 7.99 |
| Quick Ratio | 1.67 | 2.98 | 3.27 | 4.92 | 7.19 |
| Cash Ratio | 1.04 | 2.39 | 2.94 | 2.87 | 6.04 |
| Solvency Ratio | -0.32 | 0.03 | -0.52 | 0.28 | -0.64 |
| Operating Cash Flow Ratio | -0.47 | -0.82 | 0.67 | -0.89 | -2.00 |
| Short-Term Operating Cash Flow Coverage | -2.14 | -6.61 | 4.00 | -6.71 | -16.43 |
| Net Current Asset Value | NT$ 27.09M | NT$ 54.30M | NT$ 70.30M | NT$ 113.79M | NT$ 125.39M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.20 | 0.19 | 0.18 | 0.11 |
| Debt-to-Equity Ratio | 0.36 | 0.30 | 0.29 | 0.24 | 0.14 |
| Debt-to-Capital Ratio | 0.27 | 0.23 | 0.22 | 0.20 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.13 | 0.11 | 0.11 | 0.01 |
| Financial Leverage Ratio | 1.69 | 1.48 | 1.47 | 1.38 | 1.23 |
| Debt Service Coverage Ratio | -2.17 | 0.91 | -5.14 | 4.33 | -9.09 |
| Interest Coverage Ratio | -31.13 | -3.42 | -37.20 | 5.50 | -48.49 |
| Debt to Market Cap | 0.03 | 0.02 | 0.02 | 0.02 | 0.00 |
| Interest Debt Per Share | 3.66 | 3.70 | 3.72 | 4.07 | 2.68 |
| Net Debt to EBITDA | 0.31 | -8.38 | 1.50 | -1.65 | 3.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 39.24% | 51.33% | 5.21% | 42.68% | 10.26% |
| EBIT Margin | -45.78% | -3.75% | -41.60% | 13.37% | -68.19% |
| EBITDA Margin | -36.30% | 3.75% | -35.14% | 18.93% | -56.42% |
| Operating Profit Margin | -40.61% | -2.48% | -40.24% | 5.27% | -64.84% |
| Pretax Profit Margin | -47.08% | -4.47% | -43.45% | 12.32% | -69.66% |
| Net Profit Margin | -47.37% | -4.85% | -41.19% | 12.03% | -69.66% |
| Continuous Operations Profit Margin | -47.37% | -4.85% | -41.19% | 12.03% | -69.66% |
| Net Income Per EBT | 100.61% | 108.47% | 94.80% | 97.61% | 100.00% |
| EBT Per EBIT | 115.94% | 180.32% | 107.98% | 234.03% | 107.42% |
| Return on Assets (ROA) | -16.48% | -2.07% | -19.43% | 5.16% | -14.32% |
| Return on Equity (ROE) | -27.82% | -3.06% | -28.48% | 7.10% | -17.56% |
| Return on Capital Employed (ROCE) | -18.73% | -1.23% | -22.34% | 2.53% | -14.52% |
| Return on Invested Capital (ROIC) | -17.36% | -1.04% | -20.46% | 2.42% | -14.29% |
| Return on Tangible Assets | -17.01% | -2.15% | -20.39% | 5.42% | -14.82% |
| Earnings Yield | -3.81% | -0.38% | -3.11% | 0.86% | -1.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.70 | 7.43 | 14.81 | 7.40 | 6.66 |
| Payables Turnover | 1.80 | 6.78 | 7.88 | 20.74 | 25.28 |
| Inventory Turnover | 1.88 | 1.80 | 4.90 | 2.55 | 2.82 |
| Fixed Asset Turnover | 1.81 | 2.19 | 2.28 | 2.56 | 0.95 |
| Asset Turnover | 0.35 | 0.43 | 0.47 | 0.43 | 0.21 |
| Working Capital Turnover Ratio | 0.99 | 1.02 | 0.89 | 0.86 | 0.42 |
| Cash Conversion Cycle | 126.55 | 198.39 | 52.87 | 174.70 | 169.68 |
| Days of Sales Outstanding | 135.02 | 49.14 | 24.65 | 49.30 | 54.79 |
| Days of Inventory Outstanding | 194.22 | 203.09 | 74.53 | 143.00 | 129.33 |
| Days of Payables Outstanding | 202.70 | 53.84 | 46.31 | 17.60 | 14.44 |
| Operating Cycle | 329.25 | 252.23 | 99.18 | 192.30 | 184.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.93 | -2.09 | 1.87 | -2.17 | -3.75 |
| Free Cash Flow Per Share | -1.96 | -2.23 | 1.43 | -2.97 | -4.18 |
| Dividend Paid and CapEx Coverage Ratio | -57.19 | -14.39 | 4.20 | -2.69 | -8.58 |
| Capital Expenditure Coverage Ratio | -57.19 | -14.39 | 4.20 | -2.69 | -8.58 |
| Operating Cash Flow Coverage Ratio | -0.54 | -0.57 | 0.52 | -0.54 | -1.43 |
| Operating Cash Flow to Sales Ratio | -0.33 | -0.27 | 0.21 | -0.22 | -0.80 |
| Free Cash Flow Yield | -2.72% | -2.22% | 1.22% | -2.19% | -2.54% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -26.29 | -264.47 | -32.09 | 116.81 | -50.61 |
| Price-to-Sales (P/S) Ratio | 12.45 | 12.92 | 13.23 | 14.03 | 35.23 |
| Price-to-Book (P/B) Ratio | 7.31 | 8.15 | 9.15 | 8.27 | 8.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -36.77 | -45.06 | 81.68 | -45.58 | -39.43 |
| Price-to-Operating Cash Flow Ratio | -37.42 | -48.19 | 62.22 | -62.54 | -44.03 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | 2.95 | 0.08 | -0.86 | -0.06 |
| Enterprise Value Multiple | -33.98 | 336.31 | -36.17 | 72.46 | -59.14 |
| Enterprise Value | 1.02B | 1.40B | 1.59B | 1.89B | 1.82B |
| EV to EBITDA | -33.98 | 336.31 | -36.17 | 72.46 | -59.14 |
| EV to Sales | 12.33 | 12.61 | 12.71 | 13.72 | 33.37 |
| EV to Free Cash Flow | -36.44 | -43.96 | 78.43 | -44.56 | -37.35 |
| EV to Operating Cash Flow | -37.08 | -47.02 | 59.75 | -61.14 | -41.70 |
| Tangible Book Value Per Share | 9.34 | 11.65 | 11.86 | 15.29 | 17.80 |
| Shareholders’ Equity Per Share | 9.85 | 12.33 | 12.73 | 16.38 | 18.58 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.13 | 0.05 | 0.02 | 0.00 |
| Revenue Per Share | 5.79 | 7.78 | 8.80 | 9.66 | 4.68 |
| Net Income Per Share | -2.74 | -0.38 | -3.63 | 1.16 | -3.26 |
| Tax Burden | 1.01 | 1.08 | 0.95 | 0.98 | 1.00 |
| Interest Burden | 1.03 | 1.19 | 1.04 | 0.92 | 1.02 |
| Research & Development to Revenue | 0.41 | 0.28 | 0.21 | 0.16 | 0.38 |
| SG&A to Revenue | 0.39 | 0.30 | 0.25 | 0.21 | 0.37 |
| Stock-Based Compensation to Revenue | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.71 | 5.53 | -0.49 | -1.86 | 1.15 |
Currency in TWD
